Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Financing Activities (2016 - 2025)

Iradimed (IRMD) has disclosed Cash from Financing Activities for 13 consecutive years, with -$2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 14.27% to -$2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.1 million, a 24.92% increase, with the full-year FY2024 number at -$14.3 million, down 4.98% from a year prior.
  • Cash from Financing Activities was -$2.2 million for Q3 2025 at Iradimed, up from -$2.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $54154.0 in Q3 2021 to a low of -$13.3 million in Q1 2023.
  • A 5-year average of -$2.5 million and a median of -$262590.0 in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 101.7% in 2021, then tumbled 34536.13% in 2022.
  • Iradimed's Cash from Financing Activities stood at $2157.0 in 2021, then tumbled by 9300.6% to -$198457.0 in 2022, then tumbled by 32.32% to -$262590.0 in 2023, then tumbled by 820.63% to -$2.4 million in 2024, then rose by 9.32% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Cash from Financing Activities are -$2.2 million (Q3 2025), -$2.3 million (Q2 2025), and -$2.3 million (Q1 2025).